

Fig. 4 Case presentation of the typical clinical and virological courses of two representative patients who achieved HBsAg clearance after VBT occurred. **a** Patient 1, a 45-year-old man who was HBeAg+ at baseline and had genotype A. **b** Patient 2, a 38-year-old man who was HBeAg+ at baseline and had genotype A. VBT virological breakthrough

HBsAg clearance in both the HBeAg+ and – cohorts, whereas the clearance of HBsAg was associated with previous IFN therapy and the clearance of HBeAg over the first six months only in the HBeAg+ cohort, and baseline HBsAg levels only in the HBeAg– cohort.

HBV genotype was recently reported to influence declines in and the clearance of HBsAg among patients who underwent PEG-IFN therapy [31]. In one study where negativity for serum HBV DNA and seroconversion of HBeAg represented the study end point, genotype was not found to influence response to NA therapy [31]. However, other reports have indicated that genotype does impact on declines in and the clearance of HBsAg [20, 29]. Heathcote et al. [20] reported that 20 HBeAg+ patients (8 %) who were treated with tenofovir achieved HBsAg clearance in three years. Twelve (60 %) of 20 patients were infected with genotype A and the others with genotype D. In this study, cumulative HBsAg clearance rates were 15 % at year 3 in HBeAg+ patients with genotype A. This result seems to be similar regardless of the antiviral potential. Previous studies with more ethnically diverse study populations than ours found that HBsAg clearance rates were highest in patients with genotype A. The similarity between

those results and ours implies that the HBV genotype is more influential than ethnicity on HBsAg clearance during NA therapy. Of 28 genotype A patients in our population, the majority (79 %) did not have a family history of infection. Recent work has shown that sexual transmission of acute HBV genotype A infections is increasing in Japan, resulting in chronic HBV infection, especially in young adult patients [32, 33]. Cumulatively, these findings imply that HBsAg clearance is more likely in genotype A patients because they have been infected with HBV for a shorter period of time. Furthermore, Hou et al. [34] demonstrated that genotype A responded better than other HBV genotypes to IFN therapy. They revealed that a lower number of amino acid substitutions at baseline were associated with a better response to IFN therapy, and that this variable was linked with HBV genotype A, which had the lowest number of amino acid substitutions in the core gene among genotypes B, C, or D. Although amino acid substitutions in the core gene were not analyzed in this study, the relation between the core gene and treatment responses of NAs is necessary to be investigated in the future.

Although Gish et al. [19] reported that previous IFN therapy is not associated with HBsAg clearance in patients who are HBeAg+, the opposite was true in our HBeAg+ cohort. These contradictory findings may result from the fact that their patients received NA therapy over a much shorter time period (median duration 23 vs. 75 months, a 3.2-fold difference). We believe that there are two main reasons why HBsAg clearance rates were higher in patients who had previously received IFN therapy: the influence of AST/ALT flares after IFN therapy and changes in host immune response to HBV as a result of the immunomodulating activity of IFN. It has previously been shown that in patients with high baseline ALT levels, HBV DNA and HBeAg are likely to rapidly decrease during NA therapy [35, 36]. In this study, HBsAg clearance was likely to occur in patients who had high ALT levels at baseline, and in patients with previous IFN therapy (Table 2) in the HBeAg+ cohort. High virological responses have been reported in response to robust ALT flares induced by IFN therapy [37, 38]. Moreover, Wursthorn et al. [29] recently indicated that the antiviral potential of NAs and antiviral T cell reactivity are associated with HBsAg clearance in response to telbivudine treatment. These findings may be also associated with the achievement of HBsAg clearance after VBT occurs. Taken together, these results imply that both direct antiviral potential and host immune response are needed to achieve HBsAg clearance, especially in HBeAg+ patients.

We found that the initial HBsAg reduction was a strong predictor of subsequent HBsAg clearance during NA therapy, which supports a similar previous finding [29]. HBsAg reduction over the initial six months is important

for predicting the subsequent HBsAg kinetics in both HBeAg+ and HBeAg- patients. The novel finding in this study was that HBeAg- individuals achieved HBsAg clearance. We found that the median duration to HBsAg clearance was longer in patients with HBeAg- than in those who were HBeAg+ in this study (6.0 vs. 4.4 years). Manesis et al. [28] used modeling to determine that HBeAg- patients receiving LAM treatment would likely require >10 years to achieve HBsAg loss. Furthermore, baseline HBsAg titers were <730 IU/mL in 60 % (12/20) of HBeAg- patients who achieved HBsAg clearance. The only baseline predictive factor of HBsAg clearance was baseline HBsAg levels in HBeAg- patients, except for genotype. There was no difference in HBsAg clearance rates in HBeAg- patients with high- and low-baseline HBV DNA or ALT levels. We hypothesize that HBsAg clearance in these patients may result from long treatment duration and low HBsAg titers.

Our study was limited by the fact that it was a hospital-based retrospective analysis, which means there may be some bias associated with patient type and treatment selection. We were unable to compare HBsAg clearance rates obtained in our study with those of controls untreated with NA. Because all subjects in the study received LAM as an initial NA, and then received rescue therapy when drug-resistant mutations emerged, NA therapy regimens were not uniform across all patients, and there were variations in both treatment dose and duration of previous IFN therapy. We were not able to collect immunological data on our subjects. Finally, our results need to be validated by further studies investigating a large study population receiving long-term ETV or tenofovir with high antiviral potential and a high genetic barrier.

Despite these drawbacks, we were able to determine several factors associated with HBsAg clearance, including HBV genotype and a decline in HBsAg over the initial six months of treatment (HBeAg+ and - cohorts); previous IFN therapy and clearance of HBeAg over the initial six months of treatment (HBeAg+ cohort only); and HBsAg levels (HBeAg- cohort only). It seems that both direct antiviral potential and host immune response are needed to achieve HBsAg clearance by NA therapy. Future studies are needed to validate these findings and to develop treatment regimens for HBsAg clearance in patients with chronic hepatitis B.

Acknowledgments This research was partly supported by grants from the Ministry of Health, Labour and Welfare of Japan.

Conflict of interest Dr. Kumada reports having received investigator, lecture, and consulting fees from Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., MSD K.K., and Toray Co. Dr. Ikeda reports having received investigator, lecture, and consulting fees from

Dainippon Sumitomo Pharma Co. No other potential conflicts of interest relevant to this article were reported.

References

- Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. *N Engl J Med.* 2004;350:1118–29.
- Lee WM. Hepatitis B. Virus infection. *N Engl J Med.* 1997;337:1733–45.
- Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med.* 2006;354:1001–10.
- Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med.* 1999;341:1256–63.
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med.* 2003;348:800–7.
- Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med.* 1998;339:61–8.
- Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med.* 2007;357:2576–88.
- Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med.* 2006;354:1011–20.
- Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med.* 2003;348:808–16.
- Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med.* 2008;359:2442–55.
- Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical virologic response to lamivudine. *Hepatology.* 2004;40:883–91.
- Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, et al. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. *Intervirology.* 2003;46:164–70.
- Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. *J Virol.* 1995;69:3350–7.
- Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. *Virology.* 1990;175:255–61.
- Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. *J Hepatol.* 2005;42:302–8.
- Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. *Gastroenterology.* 2004;126:1750–8.
- Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. *Hepatology.* 2006;44:675–84.

18. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. *Hepatology*. 2010;51:422–30.
19. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. *J Viral Hepat*. 2010;17:16–22.
20. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. *Gastroenterology*. 2011;140:132–43.
21. Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. *J Med Virol*. 2007;79:1472–7.
22. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. *Gastroenterology*. 2009;136:486–95.
23. Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. *J Hepatol*. 2011;54:449–54.
24. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. *Gastroenterology*. 2008;135:459–67.
25. Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, et al. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. *Am J Gastroenterol*. 2009;104:2449–57.
26. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology*. 2009;136:2169–79, e2161–64.
27. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. *Hepatology*. 2009;49:1151–7.
28. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. *Antivir Ther*. 2007;12:73–82.
29. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. *Hepatology*. 2010;52:1611–20.
30. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. *Lancet*. 2002;359:1686–9.
31. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? *J Hepatol*. 2010;52:441–9.
32. Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol*. 2005;76:33–9.
33. Sugauchi F, Orito E, Ohno T, Tanaka Y, Ozasa A, Kang JH, et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. *Hepatol Res*. 2006;36:107–14.
34. Hou J, Schilling R, Janssen HLA, Hansen BE, Heijtkink R, Sablon E, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. *J Med Virol*. 2007;79:1055–63.
35. Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, Someya T, et al. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis—an open-cohort study. *J Hepatol*. 2003;38:91–7.
36. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. *Hepatology*. 2000;32:604–9.
37. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. *Gut*. 2005;54:1604–9.
38. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? *Hepatology*. 2001;34:1021–6.

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Fumitaka Suzuki · Yasuji Arase · Yoshiyuki Suzuki · Norio Akuta · Hitomi Sezaki · Yuya Seko · Yusuke Kawamura · Tetsuya Hosaka · Masahiro Kobayashi · Satoshi Saito · Kenji Ikeda · Mariko Kobayashi · Hiromitsu Kumada

Received: 5 October 2011 / Accepted: 5 January 2012 / Published online: 24 February 2012
© Springer 2012

Abstract

Background Few studies have investigated the long-term effects of interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy of and predictors of response to IFN therapy in CHB patients.

Methods We analyzed data for 615 Japanese CHB patients (hepatitis B e antigen [HBeAg]-positive 414, HBeAg-negative 201) treated with IFN, and conducted follow up for a median duration of 8.1 years (range 0.5–23.2). Responders were defined as patients who showed continuously normalized alanine transaminase (ALT) levels, HBeAg clearance, and low hepatitis B virus (HBV) DNA levels at 6 months post-treatment or for a span of more than 6 months until each test point at 1, 3, 5, and 10 years.

Results The IFN response rates of all patients were 21, 18, 21, 23, and 25% at 6 months and 1, 3, 5, and 10 years, respectively. On multivariate analysis, significant determinants of the outcome of IFN therapy were as follows: at 6 months and 1 year, young age, low HBV DNA levels, and long duration of treatment; at 3 years, long duration of

treatment, young age, and high level of albumin; at 5 years, high level of albumin, female, and pretreated with IFN; and at 10 years, HBeAg-negative. Sixty-nine of the 615 patients (11%) achieved seroclearance of hepatitis B surface antigen (HBsAg). On multivariate analysis, age ≥ 30 years, HBV genotype A, and male were all independent factors predicting the achievement of HBsAg seroclearance.

Conclusion HBeAg, HBV DNA level, age, sex, albumin, duration of treatment, pretreatment with IFN, and HBV genotype were important factors in determining long-term response to IFN therapy.

Keywords Interferon · Hepatitis B virus · Chronic hepatitis B · Genotype · Hepatitis B surface antigen

Abbreviations

CHB	Chronic hepatitis B
HBV	Hepatitis B virus
IFN	Interferon
HBeAg	Hepatitis B e antigen
ALT	Alanine transaminase
MU	Million units
HBsAg	Hepatitis B surface antigen
CLEIA	Chemiluminescent enzyme immunoassay
bDNA	Branched-chain DNA probe assay
TMA-HPA	Transcription-mediated amplification and hybridization protection assay
PCR	Polymerase chain reaction
ELISA	Enzyme-linked immunosorbent assay
AST	Aspartate transaminase
AFP	α Fetoprotein
OR	Odds ratio
CI	Confidence interval
HCC	Hepatocellular carcinoma

F. Suzuki (✉) · Y. Arase · Y. Suzuki · N. Akuta · H. Sezaki · Y. Seko · Y. Kawamura · T. Hosaka · M. Kobayashi · S. Saito · K. Ikeda · H. Kumada
Department of Hepatology, Toranomon Hospital,
2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
e-mail: fumitakas@toranomon.gr.jp

M. Kobayashi
Research Institute for Hepatology, Toranomon Hospital,
Tokyo, Japan

Introduction

Hepatitis B virus (HBV) infection is a common disease that can induce a chronic carrier state and is associated with the risk of developing progressive disease and hepatocellular carcinoma [1]. Interferon (IFN) and several nucleoside/nucleotide analogues such as lamivudine, adefovir dipivoxil, entecavir, and tenofovir disoproxil fumarate are currently approved as treatments for chronic hepatitis B (CHB) in most countries [2–5]. Successful treatment of CHB with clearance of hepatitis B e antigen (HBeAg), reduction in serum HBV DNA levels, and normalization of alanine transaminase (ALT) levels is associated with a favorable long-term outcome, independent of the antiviral drug used [6, 7].

A meta-analysis of IFN therapy published in 1993 reviewed 15 randomized controlled studies involving 837 adult patients who received IFN- α at doses of 5–10 million units (MU) administered at intervals ranging from daily to three times weekly for 4–6 months [8]. Clearance of HBeAg was noted in 33% of the treated patients compared with 12% of controls. Elimination of detectable HBV DNA and normalization of ALT levels were also more common in the treated patients than in the controls. The major pretreatment factors that correlated with a response were high ALT levels [9–11], low HBV DNA levels [9, 10], female sex, and elevated liver activity and fibrosis on liver biopsy [8]. Another recent meta-analysis of 24 randomized controlled trials concluded that the rates of persistent ALT normalization, clearance of HBeAg, and sustained elimination of HBV DNA (determined by hybridization) induced by IFN therapy were approximately 25% greater than the rates for controls. A more recent meta-analysis report showed that IFN increased the incidence of HBeAg and hepatitis B surface antigen (HBsAg) seroclearance after long-term follow up of 3–7 years [12].

However, specific data on the long-term effects of IFN therapy (median follow-up duration of 8.1 years), particularly among the Japanese, are limited. Moreover, few reports have investigated factors predicting the achievement of HBsAg seroclearance. To further evaluate factors influencing clinical outcome, we performed a retrospective cohort study on CHB patients treated with IFN in our hospital.

Patients and methods

Patients

We retrospectively examined 615 Japanese patients (151 females and 464 males) who commenced IFN treatment between June 1984 and April 2008 in the Department of

Table 1 Characteristics of patients at commencement of interferon therapy

Demographic data	
Total number	615
Sex, female/male	151/464
Age, years (range)	35 (15–68)
Previously treated with interferon	123 (20%)
Duration of treatment, weeks (range)	26 (4–981)
Follow-up period, years (range)	8.1 (0.5–23.2)
Laboratory data	
Aspartate transaminase, IU/L (range)	72 (18–990)
Alanine transaminase, IU/L (range)	138 (12–1578)
Bilirubin, mg/dL (range)	0.7 (0.2–8.8)
Albumin, g/dL (range)	3.9 (2.6–5.3)
Platelets, $\times 10^3/\mu\text{L}$ (range)	174 (48–500)
Staging of liver histology (F0/1/2/3/4/ND)	8/77/185/162/72/111
Serum HBV DNA, log copies/mL (range)	>7.6 (<2.6 to >7.6)
HBeAg (positive/negative)	414/201
HBV genotype (A/B/C/D/H/B + C/unknown)	24/37/504/1/1/1/1/47

Values are expressed as medians and ranges (in parentheses) or as numbers and percentages (in parentheses)

HBV hepatitis B virus, HBeAg hepatitis B e antigen, ND not done

Hepatology at Toranomon Hospital (Table 1). Several of the patients have been included in previous reports [13–15].

All enrolled patients were followed up for a range of 0.5–23.2 years from completion of IFN treatment, with a median follow-up duration of 8.1 years. Before the commencement of IFN treatment, all patients had been positive for HBsAg in the serum for more than 6 months, and all were confirmed to have hepatitis caused by HBV and not by another vector, such as infection with hepatitis C virus or autoimmune hepatitis. None had a history of drug abuse or alcoholic hepatitis, and none had received nucleoside/nucleotide analogue therapy. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Toranomon Hospital Ethics Committee. Informed consent was obtained from each patient.

Interferon therapy and assessment of response to therapy

Patients received 3–12 MU of IFN- α or IFN- β (Sumiferon: Dainippon Sumitomo Pharma, Osaka, Japan; Canferon A: Takeda Chemical Industries, Osaka, Japan; Intron A: Schering-Plough MSD KK, Osaka, Japan; and Feron: Toray, Tokyo, Japan). The durations and regimens of treatment were as follows: 4 weeks (89 patients; daily for

4 weeks), 26 weeks (270 patients; daily for 4 weeks followed by 2 or 3 times a week), 52 weeks (103 patients; 2 or 3 times a week), 104 weeks (80 patients; 2 or 3 times a week), and more than 104 weeks (73 patients; 2 or 3 times a week). The median duration of treatment was 26 weeks (range 4–981).

The numbers of responders were evaluated at 6 months and 1, 3, 5, and 10 years after the completion of IFN therapy. In the baseline HBeAg-positive patients, responders were defined as patients who showed normalization of serum ALT level (normal level 6–30 IU/L), HBeAg clearance, and low HBV DNA level (<5 log copies/mL) at 6 months after completion of IFN therapy. In addition, baseline HBeAg-positive patients who showed continuous normalization of ALT levels, HBeAg clearance, and low HBV DNA level for more than 6 months until each test point at 1, 3, 5, and 10 years after completion of IFN therapy were also classified as “responders.” In the baseline HBeAg-negative patients, responders were defined as those who showed sustained normalization of ALT level and low HBV DNA level (<4 log copies/mL) for more than 6 months until each test point after completion of IFN therapy.

All patients not considered to be responders were termed “non-responders.” Patients receiving other therapies (IFN or nucleoside/nucleotide analogues) after the completion of IFN therapy were also termed non-responders.

Blood tests and serum viral markers

Routine biochemical tests were performed monthly via standard procedures during and for the first 12 months following the completion of IFN treatment and at least every 2 months thereafter. Levels of HBsAg, HBeAg, and anti-HBe were determined using radioimmunoassay kits (Abbott Diagnostics, Chicago, IL, USA) or a chemiluminescent enzyme immunoassay (CLEIA; Lumipulse System; Fujirebio, Tokyo, Japan). HBV DNA levels were measured using a branched-chain DNA probe assay (bdNA) (Chiron Laboratory Service, Van Nuys, CA, USA), a transcription-mediated amplification and hybridization protection assay (TMA-HPA) (Chugai Diagnostics Science, Tokyo, Japan), or a polymerase chain reaction (PCR)-based assay (COBAS Amplicor HBV Monitor Test or COBAS TaqMan HBV Test; Roche Diagnostics, Indianapolis, IN, USA).

HBV genotype

The major genotypes of HBV were determined using an enzyme-linked immunosorbent assay (ELISA; Institute of Immunology, Tokyo, Japan) or a PCR-invader assay

(BML, Tokyo, Japan) according to the methods described by Usuda et al. [16] or Tadokoro et al. [17].

Statistical analysis

Differences between groups were examined for statistical significance using the χ^2 or Fisher’s exact test and Mann–Whitney *U*-test where appropriate. Independent predictive factors associated with response to IFN treatment were determined using multivariate multiple logistic regression. The following 14 potential predictors of response to IFN treatment were assessed in this study: age, sex, pretreatment with IFN, duration of IFN treatment, severity of liver disease (CH or liver cirrhosis), HBV genotype, and levels of aspartate transaminase (AST), ALT, bilirubin, albumin, platelets, α fetoprotein (AFP), HBeAg, and HBV DNA. All factors found to be at least marginally associated with response to IFN therapy ($P < 0.10$) were entered into the multivariate multiple logistic regression analysis. The above calculations were performed using the Windows SPSS software package version 11.0.1 J (SPSS, Chicago, IL, USA).

The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the relative risk. Independent risk factors predicting the achievement of HBsAg seroclearance were studied using stepwise Cox regression analysis. Potential factors predicting the achievement of HBsAg seroclearance assessed here were the above 14 variables, each transformed into categorical data consisting of two simple ordinal numbers for univariate and multivariate analyses. All factors found to be at least marginally associated with HBsAg seroclearance ($P < 0.10$) were tested in the multivariate Cox proportional hazard model. A Kaplan–Meier estimate was performed using the SPSS software, and *P* values were calculated using the Cox–Mantel log-rank test. A two-tailed *P* value of <0.05 was considered statistically significant.

Results

Study population

Twenty-four (4%), 37 (6%), 504 (82%), 1 (0.2%), 1 (0.2%), and 1 (0.2%) patients were infected with HBV genotypes A, B, C, D, H, and B + C, respectively. Genotype could not be measured in the remaining 47 patients. The baseline characteristics of the patients are shown in Table 1. Although few patients had genotypes A and B, the distribution of HBV genotype was similar to that in patients with CHB who had received care in our hospital, with a follow-up period of more than 2 years [18]. Twenty-two of 24 patients with genotype A, 14 of 37 with

genotype B, 342 of 504 with genotype C, 1 of 1 with genotype H, and 34 of 47 with unknown genotype were HBeAg-positive at the commencement of treatment. While we were able to measure HBV DNA levels in 254 patients at the commencement of IFN therapy, levels in the remaining 361 could not be measured owing to a lack of commercial kits before the bDNA assay was available. The numbers of patients receiving other additional therapies after the completion of IFN therapy were 111 (HBeAg-positive/-negative, 90/21), 92 (67/25), 34 (25/9), and 61 (39/22) at the 1-, 3-, 5-, and 10-year time points, respectively.

Response to interferon therapy in all patients

The IFN response rates in all patients were 21% (105/497), 18% (86/491), 21% (90/428), 23% (82/359), and 25% (59/235) at 6 months and 1, 3, 5, and 10 years, respectively, after completion of the IFN therapy (Fig. 1). In patients with genotype A, the response rate was highest at 6 months post-treatment and gradually decreased at subsequent time points from 1 to 10 years thence. In patients with genotype B, response rates were over 20% at all time points except for 6 months post-treatment, whereas rates in patients with genotype C were under 25% at all time points (Fig. 2a).

Evaluation of efficacy of IFN in relation to clinical factors in all patients

The data of all patients were subjected to univariate analyses to determine the clinical factors contributing to the efficacy of IFN at each time point. We then investigated the significance of response to IFN therapy using multivariate logistic regression analysis.

Multivariate analyses including the variables noted above revealed several parameters that independently influenced the outcome of IFN therapy; namely, at 6 months: age ($P = 0.013$), HBV DNA level ($P = 0.019$), and duration of treatment ($P = 0.034$); at 1 year: HBV DNA level ($P < 0.001$) and age ($P = 0.001$); at 3 years: duration of treatment ($P < 0.001$), age ($P = 0.013$) and albumin level ($P = 0.013$); at 5 years: albumin level ($P = 0.004$), sex ($P = 0.005$), and pretreatment with IFN ($P = 0.039$); and at 10 years: HBeAg ($P < 0.001$) (Table 2).

Response to interferon therapy and evaluation of efficacy of IFN in relation to clinical factors in HBeAg-positive patients

Response rates in baseline HBeAg-positive patients were 21% (76/370), 16% (60/367), 20% (61/305), 21% (53/247), and 18% (24/132) at 6 months and 1, 3, 5, and 10 years, respectively (Fig. 1). In patients with genotype A, the response rate was highest at 6 months post-treatment and the rate was roughly equivalent to the 6 months post-treatment rate at subsequent time points from 1 to 10 years. Response rates in patients with genotype B in particular were above 40% at all time points except at 6 months, although few patients had genotype B. On the other hand, response rates in patients with genotype C were under 20% at all time points (Fig. 2a).

In addition, multivariate analyses in HBeAg-positive patients also revealed several parameters that independently influenced the outcome of IFN therapy—at 6 months: duration of treatment ($P = 0.001$) and age ($P = 0.014$); at 1 year: age ($P = 0.011$) and HBV DNA level ($P = 0.027$); at 3 years: sex ($P = 0.008$), duration of treatment ($P = 0.019$), age ($P = 0.020$), pretreatment with IFN ($P = 0.029$), and albumin level ($P = 0.043$); at 5 years: sex ($P = 0.002$) and pretreatment with IFN ($P = 0.005$); and at 10 years, genotype ($P = 0.019$) and AST ($P = 0.035$) (Table 3).

Response to interferon therapy and evaluation of efficacy of IFN in relation to clinical factors in HBeAg-negative patients

Response rates in baseline HBeAg-negative patients were 23% (29/127), 21% (26/124), 24% (29/123), 26% (29/112), and 34% (35/103) at 6 months and 1, 3, 5, and 10 years, respectively (Fig. 1). Rates in patients with genotype C were gradually increased at subsequent time points, whereas those in patients with genotype B remained under 30% at all time points (Fig. 2b).

In addition, univariate and multivariate analyses in HBeAg-negative patients revealed that duration of treatment (≥ 1 year) independently influenced the outcome of




Fig. 1 Interferon response rates of all patients and hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients at 6 months and 1, 3, 5, and 10 years




Fig. 2 Interferon response rates of patients with genotypes A, B, and C at 6 months and 1, 3, 5, and 10 years. **a** All patients, **b** HBeAg-positive patients, **c** HBeAg-negative patients

IFN therapy at 6 months, and at 1 and 3 years. No parameters independently influenced the outcome of IFN therapy at 5 or 10 years.

Evaluation of efficacy of IFN in relation to HBs antigen seroclearance

The HBsAg seroclearance rate in this study was obtained from patients who received IFN therapy alone; 69 of 615 patients (11%) achieved seroclearance of HBsAg. The cumulative HBsAg seroclearance rates in all patients from the commencement date of IFN therapy were 6.5% at 5 years, 15% at 10 years, 35% at 15 years, and 44% at 20 years (Kaplan–Meier method; Fig. 3a). No patients experienced the reappearance of HBsAg after seroclearance. Five factors found to be associated with achievement of HBsAg seroclearance on univariate analysis were: male sex ($P = 0.002$), age ≥ 30 years ($P = 0.011$), genotype A ($P = 0.038$), HBeAg-negativity ($P = 0.045$), and bilirubin

≤ 1.0 mg/dL ($P = 0.064$). On multivariate analysis, independent factors predicting the achievement of HBsAg seroclearance were: age ≥ 30 years, genotype A, and male sex (Table 4). The cumulative HBsAg seroclearance rate for genotype A patients was significantly higher than the rate for those with genotypes B or C ($P = 0.0116$) (Fig. 3b).

Relationship between the response to IFN and the development of hepatocellular carcinoma

Twenty-nine patients developed hepatocellular carcinoma (HCC) during the observation period, excluding 17 patients who received other additional therapies after the completion of IFN therapy and developed HCC thereafter. IFN response rates in the 29 patients who developed HCC were 5% (1/22), 5% (1/20), 10% (2/20), 13% (2/15), and 13% (2/16), respectively, at 6 months and 1, 3, 5, and 10 years after the completion of IFN. No patient developed HCC after HBsAg seroclearance.

Table 2 Factors associated with response to interferon therapy for all patients at 6 months and 1, 3, 5, and 10 years

Parameter	Univariate analysis		Multivariate analysis	
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
6 Months after completion of IFN therapy (<i>n</i> = 229)				
Duration of treatment (≥1 year)	2.680 (1.724–4.166)	<0.001	2.107 (1.058–4.198)	0.034
HBV DNA level (≤7.0 log copies/mL)	2.165 (1.107–4.219)	0.026	2.309 (1.148–4.630)	0.019
Age (<30 years)		0.057	2.451 (1.209–4.950)	0.013
1 year after completion of IFN therapy (<i>n</i> = 231)				
Duration of treatment (≥1 year)	2.553 (1.588–4.104)	<0.001		
HBV DNA level (≤7.0 log copies/mL)	3.268 (1.597–6.667)	0.001	4.464 (2.058–9.709)	<0.001
Age (<35 years)	1.799 (1.125–2.874)	0.014	3.831 (1.718–8.547)	0.001
3 years after completion of IFN therapy (<i>n</i> = 397)				
Duration of treatment (≥1 year)	2.410 (1.495–3.885)	<0.001	2.739 (1.618–4.634)	<0.001
Age (<30 years)	2.070 (1.215–3.521)	0.009	2.110 (1.171–3.802)	0.013
Albumin (≥3.9 g/dL)	1.697 (1.045–2.757)	0.030	2.009 (1.158–3.486)	0.013
Genotype (non-C)	2.155 (1.033–4.504)	0.041		
5 years after completion of IFN therapy (<i>n</i> = 356)				
Albumin (≥3.9 g/dL)	1.869 (1.108–3.153)	0.017	2.321 (1.316–4.093)	0.004
Pretreatment with IFN (positive)	1.770 (1.016–3.084)	0.048	1.821 (1.029–3.222)	0.039
Sex (female)		0.060	2.381 (1.297–4.367)	0.005
Duration of treatment (≥1 year)		0.080		
10 years after completion of IFN therapy (<i>n</i> = 234)				
HBeAg (negative)	2.315 (1.269–4.219)	0.006	2.252 (1.230–4.115)	0.009
ALT (≥100 IU/L)	1.972 (1.053–3.690)	0.036		
Pretreatment with IFN (positive)		0.058		

ALT alanine transaminase, IFN interferon, HBV hepatitis B virus, HBeAg hepatitis B e antigen, CI confidence interval, OR odds ratio, *n* number submitted to multivariate analysis, including all factors found to be associated with response to IFN therapy

Discussion

Although IFN has been reported to exert beneficial effects in CHB patients, the response rate is not high. A meta-analysis published in 1993 reviewed 15 randomized controlled studies involving 837 adult patients who received IFN-α for 4–6 months, and elimination of HBeAg occurred in 33% of the treated patients [8]. In previous studies, we found the response rates among HBeAg-positive patients at 6 months after the completion of therapy to be 20 and 31% for 6 months and 1 year of IFN therapy, respectively [13, 15]. Although a recent meta-analysis reported that IFN increased the incidence of HBeAg and HBsAg seroclearance after long-term follow up of 3–7 years [12], the factors that influenced the clinical outcome were unclear.

In Japan, from 1988, 4-week IFN treatment was reimbursed by the healthcare system, and since 2002, 24-week IFN treatment has been conducted. In the present study, these two regimens were the major ones, and other regimens were used in clinical studies at our hospital (including previously reported studies [14, 15]). Although the durations of treatment differed, we analyzed the factors

associated with long-term response to IFN therapy, including the factor of duration of treatment.

In the present study, response rates were low among HBeAg-positive patients and relatively high among HBeAg-negative patients at all time points. Approximately 20% of the HBeAg-positive patients had sustained a response at 6 months to 10 years of follow up. Long-term follow-up studies after a four- to six-month course of IFN therapy in HBeAg-positive patients in European and Taiwanese studies showed higher (33–75%) response rates (HBeAg loss) than our study [7, 19, 20]. The difference in response rates between our present study and previous studies in other countries may be due to differences in ethnicity or HBV genotype (mainly genotype C in Japan). Moreover, the low IFN response rates at 1, 3, 5, and 10 years in the HBeAg-positive patients in our study were likely due to the change in treatments (IFN or nucleoside/nucleotide analogues). On the other hand, the response rates of HBeAg-negative patients in the present study were about 20% at 6 months and gradually increased thereafter. The sustained response rate in HBeAg-negative patients was usually <30% in European studies [21–23]. The response

Table 3 Factors associated with response to interferon therapy for HBeAg-positive patients at 6 months and 1, 3, 5, and 10 years

Parameter	Univariate analysis		Multivariate analysis	
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
6 months after completion of IFN therapy (<i>n</i> = 279)				
Duration of treatment (≥1 year)	2.449 (1.457–4.114)	0.001	2.801 (1.540–5.096)	0.001
Age (<35 years)	1.855 (1.112–3.096)	0.017	2.128 (1.164–3.891)	0.014
1 year after completion of IFN therapy (<i>n</i> = 172)				
Duration of treatment (≥1 year)	2.483 (1.407–4.380)	0.002		
HBV DNA level (≤7.0 log copies/mL)	3.509 (1.495–8.264)	0.005	3.003 (1.130–7.937)	0.027
Age (<35 years)	1.996 (1.133–3.521)	0.015	3.610 (1.351–9.615)	0.011
3 years after completion of IFN therapy (<i>n</i> = 283)				
Age (<35 years)	2.041 (1.155–3.597)	0.013	2.083 (1.122–3.861)	0.020
Duration of treatment (≥1 year)	2.055 (1.153–3.661)	0.016	2.130 (1.132–4.008)	0.019
Pretreatment with IFN (positive)	2.054 (1.050–4.019)	0.041	2.336 (1.091–4.998)	0.029
Albumin (≥3.9 g/dL)		0.055	1.974 (1.020–3.820)	0.043
Sex (female)		0.089	2.646 (1.284–5.464)	0.008
5 years after completion of IFN therapy (<i>n</i> = 247)				
Sex (female)	2.571 (1.328–4.975)	0.006	2.924 (1.477–5.814)	0.002
Pretreatment with IFN (positive)	2.460 (1.213–4.988)	0.015	2.870 (1.377–5.980)	0.005
10 years after completion of IFN therapy (<i>n</i> = 122)				
Genotype (non-C)	5.319 (1.222–23.26)	0.032	6.410 (1.364–30.30)	0.019
AST (≥100 IU/L)		0.081	2.932 (1.078–7.972)	0.035

AST aspartate transaminase, IFN interferon, HBV hepatitis B virus, HBeAg hepatitis B e antigen, CI confidence interval, OR odds ratio, *n* number submitted to multivariate analysis, including all factors found to be associated with response to IFN therapy

rates of HBeAg-negative patients in our present study and the studies in other countries [21–23] were similar.

Few reports have identified the factors associated with long-term virological response to IFN therapy. In our present study, HBeAg-negativity was the most important factor for predicting a long-term response (10 years). While the HBV DNA level was important for predicting the response at 6 months and 1 year for all patients and the response at 1 year for HBeAg-positive patients, other factors (age, sex, albumin level, AST, IFN pretreatment, and duration of treatment) were found to be important at some time points for all patients and for HBeAg-positive patients. The HBV DNA level may not have been associated with long-term response to IFN therapy because the follow-up period (median 5.7 years) in patients with an HBV DNA level measurable with commercial kits was significantly shorter than that in the other patients (median 11.2 years; $P < 0.001$).

Previous studies have reported that high ALT levels, low HBV DNA level, female sex, and elevated liver activity and level of fibrosis on liver biopsy were major pretreatment factors correlated with a response to IFN [8–11, 24]. However, in these studies the follow-up times for judging the response were short (typically 6 months to 1 year). Our present study has clarified that HBeAg, HBV DNA level, age, sex, IFN pretreatment, duration of treatment, and levels of albumin and AST are important factors in the

long-term response to IFN. Further, non-C genotype was an important factor for long-term response in HBeAg-positive patients. Kao et al. [25] and Lin et al. [20] reported that HBV genotype B was associated with a higher response rate to IFN- α therapy than genotype C among CHB patients positive for HBeAg. Similarly, response rates among HBeAg-positive patients with genotype B in the present study were also higher than the response rates in those with genotype C in terms of long-term response (Fig. 2b). The long-term response rate among HBeAg-negative patients was relatively higher than that in HBeAg-positive patients. Previous reports have shown that response rates to a 6- to 12-month course of IFN- α in HBeAg-negative CHB patients range from 10 to 47% (average 24%) [26–29]. In addition, our previous report showed that 9 of 12 (75%) patients who received IFN- β twice per week for 24 weeks responded to the therapy [14]. However, the follow-up periods of these studies were short, and the long-term efficacy has not been clarified. While the efficacy of IFN in HBeAg-negative patients was high in the present study, the factors that might be useful in predicting a sustained response were less well-defined than those in HBeAg-positive patients, as previously reported [5].

A meta-analysis of IFN therapy published in 2010 reviewed 6 clinical controlled studies including 828 patients who received IFN [12]. The duration of follow-up




Fig. 3 Cumulative clearance of hepatitis B surface (HBs) antigen in patients treated with interferon (Kaplan–Meier method). **a** All patients, **b** patients stratified by genotypes A, B, and C

Table 4 Factors associated with HBsAg seroclearance by interferon therapy, determined by multivariate analysis

Parameter	Category	Hazard ratio	95% CI	P
Age	<30 years	1		0.002
	≥30 years	4.433	1.703–11.538	
Genotype	A	1		0.004
	B	0.296	0.087–1.005	
	C	0.199	0.075–0.528	
Sex	Female	1		0.005
	Male	2.962	1.387–6.327	

HBsAg hepatitis B surface antigen, CI confidence interval

ranged from 35.8 months to 7 years, and HBsAg seroclearance occurred in 9.5% (79/828). In the present study, we observed HBsAg seroclearance in 69 of 615 (11%)

patients, with a median follow-up duration of 8.1 years. However, few reports have investigated factors predicting the achievement of HBsAg seroclearance. In our study, important factors for achieving HBsAg seroclearance were age ≥30 years, genotype A, and male sex. Patients with genotype A had primarily been infected during adulthood via sexual contact, and the average duration of infection was relatively short. In contrast, most Japanese carriers are infected perinatally and possess HBV genotype C, and therefore the efficacy of IFN therapy for patients with genotype C may be low. Male sex was also an important factor in determining potential to achieve HBsAg seroclearance, although female sex was an important factor in determining long-term response to IFN therapy. In our previous study of HBsAg seroclearance (mainly spontaneous seroclearance), we found that response rates were low among females (19%; 45/231) [30]. These present and previous findings indicate that male patients tended to achieve HBsAg seroclearance more frequently than females, although the reason is unclear. We previously reported that Kaplan–Meier analysis in 486 patients who received lamivudine therapy for 5 and 10 years showed an estimated loss of HBsAg in 3 and 13% of the patients, respectively, [31]. The cumulative clearance rates of HBsAg, also determined by Kaplan–Meier analysis, in patients treated with IFN were higher than those in the patients treated with lamivudine, albeit that there were differences in the baseline characteristics of the patients at the commencement of the respective therapies. The effects of IFN therapy in modulating the host immune response might induce HBsAg clearance.

In conclusion, we investigated the long-term efficacy of IFN therapy in Japanese CHB patients. Response rates were low among HBeAg-positive patients and relatively high among HBeAg-negative patients at all time points examined. HBeAg-negative status, HBV DNA level, age, sex, pretreatment with IFN, duration of treatment, and levels of albumin and AST were important factors in predicting long-term response for all patients and for HBeAg-positive patients. Age, genotype, and sex were important factors in predicting ability to achieve HBsAg seroclearance. Further studies exploring the efficacy of therapy over a longer duration may be necessary to confirm these findings and establish true response rates to IFN therapy, including treatment with pegylated IFN.

Acknowledgments This study was supported in part by a Grant-in-aid from the Ministry of Health, Labor and Welfare of Japan. These authors disclose the following: Dr. Kumada reports having received investigator, lecture, and consulting fees from Dainippon Sumitomo Pharma Co., MSD KK, and Toray Co. Dr. Ikeda reports having received investigator, lecture, and consulting fees from Dainippon Sumitomo Pharma Co. No other potential conflicts of interest relevant to this article were reported.

References

1. Beasley RP, Hwang LW, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. *Lancet*. 1981;2:1129–233.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. *N Engl J Med*. 1995;333:1657–61.
3. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med*. 2003;348:808–16.
4. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med*. 2006;354:1001–10.
5. Lok ASF, Heathcote EJ, Hoofnagel JH. Management of hepatitis B: 2000—summary of a workshop. *Gastroenterology*. 2001;120:1828–53.
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med*. 2004;351:1521–31.
7. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology*. 2004;39:804–10.
8. Wong DHK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. *Ann Intern Med*. 1993;119:312–23.
9. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? *Hepatology*. 1989;10:761–3.
10. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. *N Engl J Med*. 1990;323:295–301.
11. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. *Hepatology*. 2002;36:186–94.
12. Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. *Antiviral Res*. 2010;85:361–5.
13. Suzuki F, Arase Y, Akuta N, Tsubota A, Suzuki Y, Sezaki H, et al. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. *J Gastroenterol*. 2004;39:969–74.
14. Arase Y, Chayama K, Tsubota A, Murashima N, Suzuki Y, Koida I, et al. A randomized, double-blind, controlled trial of natural interferon- α therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels. *J Gastroenterol*. 1996;31:559–64.
15. Arase Y, Tsubota A, Saitoh S, Suzuki Y, Kobayashi M, Suzuki F, et al. Randomized, controlled trial of natural interferon- α therapy for e-antigen-positive chronic hepatitis B patients. *Hepatol Res*. 2002;23:98–104.
16. Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. *J Virol Method*. 1999;80:97–112.
17. Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, et al. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. *J Virol Method*. 2006;138:30–9.
18. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B and C. *J Gastroenterol*. 2002;37:35–9.
19. Niderau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med*. 1996;334:1422–7.
20. Lin SM, Yu KL, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. *J Hepatol*. 2007;46:45–52.
21. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon- α treated and untreated patients with HBeAg-negative chronic hepatitis B. *J Hepatol*. 2001;34:306–13.
22. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. *J Hepatol*. 2002;36:263–70.
23. Lampertico P, Ninno ED, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. *Hepatology*. 2003;37:756–63.
24. Lau DTY, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. *Gastroenterology*. 1997;113:1660–7.
25. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. *J Hepatol*. 2000;33:998–1002.
26. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis B. *J Hepatol*. 1990;11:S133–6.
27. Pastore G, Santantonio T, Milella A, Monno L, Mariano N, Moschetta R, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in serum: response to a 6-month course of lymphoblastoid interferon. *J Hepatol*. 1992;20:221–5.
28. Fattovich G, Farci P, Rugge M, Brollo G, Mandas A, Pontisso P, et al. A randomized, controlled trial of lymphoblastoid interferon- α in patients with chronic hepatitis B lacking HBeAg. *Hepatology*. 1992;15:584–9.
29. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. *Hepatology*. 1997;26:1621–5.
30. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. *Am J Med*. 2006;119:71 e9–e16.
31. Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, et al. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. *J Med Virol*. 2007;79:1472–7.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients

Atsushi Ono¹, Fumitaka Suzuki^{1,*}, Yusuke Kawamura¹, Hitomi Sezaki¹, Tetsuya Hosaka¹, Norio Akuta¹, Masahiro Kobayashi¹, Yoshiyuki Suzuki¹, Satoshi Saitou¹, Yasuji Arase¹, Kenji Ikeda¹, Mariko Kobayashi², Sachiyo Watahiki², Rie Mineta², Hiromitsu Kumada¹

¹Department of Hepatology, Toranomon Hospital, Tokyo, Japan; ²Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan

Background & Aims: We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection.

Methods: The cumulative rates of undetectable hepatitis B virus DNA (HBV DNA; $<2.6 \log_{10}$ copies/ml), hepatitis B e antigen (HBeAg) seronegativity, seroconversion, alanine aminotransferase (ALT) normalization, and entecavir signature mutations were calculated in 474 nucleos(t)ide-naïve CHB patients (HBeAg-positive: 47%) on continuous entecavir treatment for 4 years.

Results: Median age was 47 years and follow-up period was 2.4 years, with 403, 281, 165, and 73 patients followed-up for at least 1, 2, 3, and 4 years, respectively. Incremental increases were observed in the rates of undetectable HBV DNA, HBeAg seroclearance and seroconversion, and ALT normalization, reaching 96%, 42%, 38% and 93%, respectively, by the fourth year. In all, 100% and 93% of patients negative and positive for HBeAg, respectively, had undetectable HBV DNA at year 4. Of 165 patients, HBV DNA was detectable in nine patients after 3 years. Multivariate analysis identified HBV DNA level ($\leq 7.6 \log_{10}$ copies/ml, OR = 15.8; 95% CI = 43.1–79.9, $P = 0.001$) as an independent predictor of undetectable HBV DNA at year 3. Five patients experienced virological breakthrough including two (0.4%) who developed entecavir-resistance mutations.

Conclusions: Continuous treatment of nucleos(t)ide-naïve CHB patients with entecavir over 4 years was associated with 96% chance of undetectable HBV DNA and only 0.4% chance of emerging entecavir-resistant mutations.

© 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Introduction

Approximately 350–400 million people worldwide have chronic hepatitis B (CHB) infection, the majority of whom live in the Asia–Pacific region [1,2]. CHB patients with elevated viral load are at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma.

Recent investigations have shown that entecavir suppressed HBV DNA replication to undetectable levels and normalized alanine aminotransferase (ALT) levels in nucleos(t)ide-naïve CHB patients in Japan and other countries [3–10]. In addition, genotypic resistance to long-term entecavir monotherapy remained rare [5,6,9,10]. To date, there are two 5-year studies [6,8] and two 3-year studies [7,9] of entecavir therapy for nucleos(t)ide-naïve patients. Both studies stemmed from extension studies with the original cohorts from two large-scale phase III trials of treatment-naïve patients [3,4]. In these trials, patients were administered 0.5 mg entecavir for 1 year and later divided into three categories: (i) complete responders, defined as patients with HBV DNA $<7 \times 10^5$ copies/ml and ALT level <1.25 times the upper limit of normal (ULN) for hepatitis B e antigen (HBeAg)-negative patients and an additional loss of HBeAg for HBeAg-positive patients; (ii) non-responders, defined as HBV DNA $\geq 7 \times 10^5$ copies/ml; and, (iii) virological responders, defined as HBV DNA $<7 \times 10^5$ copies/ml and ALT $>1.25 \times$ ULN regardless of HBeAg status or persistent HBeAg for HBeAg-positive patients. Treatment was terminated in the complete responders but continued in virological responders. Non-responders were provided additional therapy in a rollover study in which some patients were initially treated with a combination of 1 mg entecavir and lamivudine for several months before receiving 1 mg entecavir as monotherapy. Furthermore, a substantial proportion of complete responders relapsed after various intervals following cessation of therapy and they were also assigned to a rollover study receiving 1 mg entecavir monotherapy. Because of these strict protocols, the precise viral-suppression and drug-resistance data for treatment-naïve patients who were treated continuously with 0.5 mg entecavir daily (the recommended dosage) remain unavailable.

The aims of this cohort study were (1) to investigate the efficacy of entecavir in clinical practice beyond 4 years for nucleos(t)ide-naïve CHB and cirrhosis patients, (2) to explore baseline factors associated with virological response to entecavir,

Keywords: Hepatitis B virus; Entecavir; Resistance; Virological breakthrough.
Received 29 September 2011; received in revised form 12 April 2012; accepted 18 April 2012; available online 30 May 2012

* Corresponding author. Address: Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan. Tel.: +81 (44) 877 5111; fax: +81 (44) 860 1623.

E-mail address: fumitakas@toranomon.gr.jp (F. Suzuki).

Abbreviations: AFP, α fetoprotein; ALT, alanine aminotransferase; AST, aspartate transaminase; CHB, chronic hepatitis B; CIs, confidence intervals; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HBV DNA, hepatitis B virus DNA; ORs, odds ratios; PCR, polymerase chain reaction; ULN, upper limit of normal; VBT, virologic breakthrough.



and (3) to investigate virological breakthrough during long-term entecavir treatment.

Patients and methods

Study population

We performed a retrospective analysis of 474 CHB and cirrhosis patients who received entecavir treatment at the Department of Hepatology, Toranomon Hospital, Tokyo, from March 2004 to May 2011, and adhered to the treatment for more than 6 months (Table 1). All patients were negative for hepatitis C serological markers, but all had detectable HBV surface antigen (HBsAg) for at least 6 months prior to the start of entecavir therapy. Two patients received 0.01 mg entecavir and one patient received 0.1 mg entecavir for 24 weeks, prior to 0.5 mg/day from a phase II study ETV-047 in Japan [11]. The other patients received 0.5 mg entecavir. None had received other nucleos(t)ide analogs. The diagnosis of chronic hepatitis and cirrhosis was established by needle biopsy, peritoneoscopy, or clinically before treatment. The clinical criteria for chronic hepatitis included elevated ALT levels over 6 months and absence of clinical evidence of portal hypertension, such as esophageal varices, ascites, hepatic encephalopathy, and features suggestive of cirrhosis on ultrasonography. Chronic hepatitis and cirrhosis were diagnosed in 374 and 102 patients, respectively. Twenty-eight patients were lost to follow-up, including 10 patients who moved to other locations, seven who never visited the hospital again, two who became pregnant, four who died, four who had virological breakthrough (VBT), and one who showed disappearance of HBsAg. Moreover, 18 patients developed HCC during treatment and their data until loss to follow-up or diagnosis of HCC were analyzed. Informed consent was obtained from each patient enrolled in the study and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Toranomon Hospital Ethical Committee.

Analysis of treatment efficacy

The clinical efficacy of entecavir was assessed as the proportion of patients who achieved HBV DNA suppression to undetectable levels ($<2.6 \log_{10}$ copies/ml), and those who achieved ALT normalization ($<1 \times$ ULN). HBV DNA was measured using

Table 1. Characteristics of patients at the start of entecavir therapy. Table data are number of patients or median (range).

Demography	
n	474
Sex, male/female	321/153
Age, yr	47 (17-82)
Family history of HBV	291 (61%)
Cirrhosis	102 (22%)
Median duration of treatment, yr (range)	2.37 (0.5-7.2)
Laboratory data	
AST, IU/L	52 (14-1595)
ALT, IU/L	70 (8-2121)
Bilirubin, mg/dl	0.7 (0.2-3.9)
γ -GTP, IU/L	38 (9-679)
Albumin, g/dl	3.9 (1.9-5.1)
Alpha fetoprotein, ng/ml	5 (1-379)
Viral load, \log_{10} copies/ml	6.7 (<2.6 - >9.0)
HBeAg-positive	222 (47%)
HBV genotypes, A/B/C/H/unknown	12/67/336/2/57

the polymerase chain reaction (PCR)-based Amplicor HBV Monitor assay (Roche Diagnostics, Indianapolis, IN, lower limit of detection of $2.6 \log_{10}$ copies/ml) [12]. HBeAg seroclearance and seroconversion were also analyzed. Measurements were made on stored samples taken at baseline and every year after that since entecavir treatment initiation.

Statistical analysis

Differences between groups were examined for statistical significance using the χ^2 test where appropriate. Spearman correlation coefficient (two-tailed) was used to evaluate the correlation between albumin and other factors. Independent predictive factors associated with response to entecavir treatment were determined using multivariate multiple logistic regression. The following 12 potential predictors of response to entecavir treatment were assessed in this study: age, sex, severity of liver disease (CH or cirrhosis), HBV genotype, as well as levels of aspartate transaminase (AST), ALT, bilirubin, albumin, platelets, α fetoprotein (AFP), HBeAg, and HBV DNA. All factors found to be at least marginally associated with undetectable levels of HBV DNA after 1-4 years ($p < 0.10$) were entered into the multivariate multiple logistic regression analysis. The above calculations were performed using The Statistical Package for Social Sciences version 11.0.1 (SPSS Inc, Chicago, IL).

The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the relative risk confidence. Independent risk factors predicting achievement of HBeAg seroclearance and seroconversion were analyzed using stepwise Cox regression analysis. Potential factors that could predict achievement of HBeAg seroclearance assessed here were the above 11 variables, each transformed into categorical data consisting of two simple ordinal numbers for univariate and multivariate analyses. All factors found to be at least marginally associated with HBeAg seroclearance and seroconversion ($p < 0.10$) were tested in the multivariate Cox proportional hazard model. A Kaplan-Meier estimate was performed using the SPSS software, and p values were calculated using the Cox-Mantel log-rank test. The Mann-Whitney U test was used for comparison of HBV DNA levels in patients with seroconversion to those with seroclearance. A two-tailed p value < 0.05 was considered statistically significant.




Fig. 1. Percentages of patients who had undetectable levels of HBV DNA between years 1 through 4. (A) HBeAg-positive and negative patients and (B) patients with genotype A, B, or C.

Research Article

Table 2. Univariate and multivariate analyses of host and viral factors associated with undetectable levels of HBV DNA at year 1.

Parameter	Univariate analysis		Multivariate analysis	
	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value
Sex (female)	1.06 (0.56-2.02)	0.842		
Age (>40 yr)	1.85 (1.0-3.4)	0.047		
Cirrhosis (present)	2.39 (0.98-5.81)	0.048		
Albumin (>4 g/dl)	1.28 (0.63-2.62)	0.494		
Bilirubin (>1.2 g/dl)	1.63 (0.56-4.76)	0.366		
ALT (>5 x IU/L)	4.57 (1.38-15.1)	0.007	11.9 (3.3-41.7)	<0.001
AST (>5 x IU/L)	2.25 (0.67-7.53)	0.178		
γ -GTP (\leq 20 IU/L)	1.75 (0.60-5.08)	0.300		
AFP (>10 ng/ml)	1.63 (0.61-4.37)	0.328		
Platelets (\leq 10/mm ³)	2.39 (0.56-10.3)	0.288		
Genotype (B)	9.57 (1.29-70.92)	0.007		
HBeAg (negative)	23.78 (7.25-77.95)	<0.001	8.5 (2.3-31.2)	0.001
HBV DNA (\leq 7.6 log ₁₀ copies/ml)	16.5 (8.0-34.2)	<0.001	10.0 (4.3-23.1)	<0.001

Table 3. Univariate and multivariate analyses of host and viral factors associated with undetectable levels of HBV DNA at year 2.

Parameter	Univariate analysis		Multivariate analysis	
	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value
Sex (male)	0.524 (0.169-1.627)	0.257		
Age (>40 yr)	2.825 (1.1-7.25)	0.025		
Cirrhosis (present)	3.06 (0.69-13.5)	0.173		
Albumin (\leq 3.5 g/dl)	4.64 (0.603-35.73)	0.134		
Bilirubin (\leq 0.5 g/dl)	2.80 (0.79-9.93)	0.126		
ALT (>5 x IU/L)	5.35 (0.7-40.9)	0.054	16.7 (2.0-136.8)	0.009
AST (>5 x IU/L)	2.62 (0.34-20.3)	0.298		
γ -GTP (\leq 100 IU/L)	1.79 (0.557-5.73)	0.304		
AFP (>15 ng/ml)	2.12 (0.27-16.95)	0.699		
Platelets (\leq 12/mm ³)	4.74 (0.619-36.31)	0.136		
Genotype (B)	1.082 (1.042-1.123)	0.076		
HBeAg (negative)	23.21 (3.05-176.46)	<0.001		
HBV DNA (\leq 7.6 log ₁₀ copies/ml)	39.91 (8.912-178.76)	<0.001	121.7 (15.3-965.9)	<0.001

Results

Study population

Of the 474 subjects in this study, 68% were males, and the mean age was 47 years. The mean HBV DNA level was 6.7 log₁₀ copies/ml, mean ALT level was 70 IU/L, and 47% of patients were HBeAg-positive. At baseline, there were 12, 67, and 336 patients of genotype A, B, and C, respectively, and among the patients belonging to these genotypes, 4, 11, and 188, respectively, were HBeAg-positive.

Virological response

Undetectable levels of HBV DNA were identified at years 1 through 4 in 88% (353/402), 93% (262/281), 95% (156/165), and

96% (70/73) of patients, respectively (Fig. 1A). Among the HBeAg-positive patients at baseline, 75% (138/184), 86% (114/132), 89% (75/84), and 93% (38/41), and among the HBeAg-negative patients at baseline, 99% (214/217), 99% (147/148), 100% (80/80), and 100% (32/32) had undetectable levels of HBV DNA at years 1 through 4, respectively.

Among the patients with genotype A, 78% (7/9), 88% (7/8), 100% (4/4), and 100% (3/3) of patients had undetectable levels of HBV DNA at years 1 through 4, respectively (Fig. 1B). Among the HBeAg-positive patients with genotype A at baseline, 50% (2/4), 67% (2/3), 100% (2/2), and 100% (2/2) had undetectable levels of HBV DNA at years 1 through 4, respectively. Among patients with genotype B, 98% (55/56), 100% (39/39), 100% (17/17), and 100% (4/4) had undetectable levels at years 1 through 4, respectively (Fig. 1B). Among the HBeAg-positive patients with genotype B at baseline, 88% (7/8), 100% (5/5), and 100% (3/3) had




Fig. 2. Percentages of patients with ALT level $<1 \times$ upper limit of normal level (ULN), $1-2 \times$ ULN, $2-5 \times$ ULN, and $5 \times$ ULN.

undetectable levels of HBV DNA at years 1 through 3, respectively. None of the patients with genotype B at baseline were HBeAg-positive at year 4. Among the patients with genotype C, 85% (246/288), 93% (201/217), 95% (125/132), and 95% (62/65) had undetectable levels of HBV DNA at years 1 through 4, respectively (Fig. 1B), and of these, 74% (116/156), 87% (102/117), 91% (67/74), and 92% (35/38), respectively, were HBeAg-positive.

Factors associated with detectable levels of HBV DNA at years 1, 2, and 3

Of the 402 patients, 353 had no detectable HBV DNA after 1 year. At the start of treatment, factors associated with undetectable levels of HBV DNA in the first year were age (>40 years, $p = 0.047$), cirrhosis (present, $p = 0.048$), ALT ($>5 \times$ ULN, $p = 0.007$), genotype (B, $p = 0.007$), HBeAg (negative, $p < 0.001$), and HBV DNA level ($<7.6 \log_{10}$ copies/ml, $p < 0.001$), by univariate analysis (Table 2). Multivariate analysis identified three param-

eters, namely ALT ($>5 \times$ ULN, OR = 11.9; 95% CI = 3.3–41.7, $p < 0.001$), HBeAg (negative, OR = 8.5; 95% CI = 2.3–31.2, $p = 0.001$), and HBV DNA level ($<7.6 \log_{10}$ copies/ml, OR = 10.0; 95% CI = 4.3–23.1, $p < 0.001$).

Of 281 patients, HBV DNA was undetectable in 262 patients in the second year, with univariate analysis identifying the following associated factors: age (>40 years, $p = 0.025$), ALT ($>5 \times$ ULN, $p = 0.054$), HBeAg (negative, $p < 0.001$), and HBV DNA level ($\leq 7.6 \log_{10}$ copies/ml, $p < 0.001$). Of these, multivariate analysis identified ALT ($>5 \times$ ULN, OR = 16.7; 95% CI = 2.0–136.8, $p = 0.009$) and HBV DNA level ($\leq 7.6 \log_{10}$ copies/ml, OR = 121.7; 95% CI = 15.3–965.9, $p < 0.001$) as significant factors (Table 3).

Of 165 patients, HBV DNA was undetectable in 156 patients in the third year, with univariate analysis identifying the following associated factors at the start of treatment: Gender (male, $p = 0.04$), HBeAg (negative, $p = 0.002$) and HBV DNA level ($\leq 7.6 \log_{10}$ copies/ml, $p < 0.001$). Multivariate analysis identified only HBV DNA level as significant ($\leq 7.6 \log_{10}$ copies/ml, OR = 15.8; 95% CI = 43.1–79.9, $p = 0.001$).

Biochemical response

The percentages of patients with normal ALT levels ($<1 \times$ ULN) at years 1, 2, 3, 4 were 83% (336/403), 89% (251/281), 92% (151/165), and 93% (68/73), respectively (Fig. 2). In HBeAg-positive patients at baseline, those who achieved normal ALT levels at years 1, 2, 3, 4 were 81% (148/183), 88% (116/132), 90% (76/84), and 95% (39/41), respectively. The respective data for HBeAg-negative patients at baseline were 85% (187/219), 91% (134/148), 93% (74/80), and 91% (29/32).

HBeAg seroclearance and seroconversion

HBeAg positivity at baseline was detected in 222 patients (47%) (Table 1), and Fig. 3A shows the cumulative clearance of HBeAg calculated with the Kaplan–Meier method. The percentages of patients with seroclearance were 16%, 24%, 37%, and 42% at years 1 through 4, respectively. Univariate analysis identified the following HBeAg seroclearance-associated factors at the start of treatment: age (>40 years, $p = 0.052$), platelet count ($<12 \times 10^4/\text{mm}^3$, $p = 0.028$), and HBV DNA ($<7.0 \log_{10}$ copies/ml, $p = 0.006$). Multivariate analysis identified HBV DNA ($<7 \log_{10}$ copies/ml, RR = 1.9; 95% CI = 1.2–3.1, $p = 0.007$) as the only significant determinant of seroclearance. Of 70 patients who achieved anti-HBe seroclearance, 52 patients achieved anti-HBe seroconversion. Fig. 3B shows the cumulative seroconversion rate of HBeAg calculated by the Kaplan–Meier test. The proportions of patients who showed seroconversion were 12%, 18%, 29%, and 38% at years 1 through 4, respectively. Univariate analysis demonstrated that age (>40 years, $p = 0.020$), albumin ($<3.5 \text{ g/dl}$, $p = 0.021$) and platelet count ($<20 \times 10^4/\text{mm}^3$, $p = 0.067$) correlated with HBeAg seroconversion at the start of treatment. Multivariate analysis that included the above factors identified serum albumin as the only significant determinant of seroconversion ($<3.5 \text{ g/dl}$, RR = 2.0; 95% CI = 1.1–3.6, $p = 0.019$). One patient achieved anti-HBe seroconversion at 25 months but became positive again at 28 months. Other patients who achieved anti-HBe seroconversion did not show HBeAg reversion. One patient achieved anti-HBe seroconversion but remained HBV DNA positive (Table 4, Patient 5). Another patient remained positive for HBV




Fig. 3. Change of the HBeAg status during follow-up. Cumulative rates of (A) HBe seroclearance and (B) HBe seroconversion in HBeAg-positive patients, analyzed with the Kaplan–Meier test.

Research Article




Fig. 4. Cumulative rates of patients who showed resistance to therapy analyzed with the Kaplan-Meier test. (A) Virologic breakthrough (VBT) and (B) entecavir-resistance.

DNA after anti-HBe seroconversion. One patient became negative for HBsAg at week 28.

Monitoring resistance to treatment

Five patients showed VBT during the treatment period, including two patients (Patient 1 had been reported previously [13]) who developed entecavir-resistant mutations. None of the five patients had mutation(s) for entecavir at baseline. VBT was defined as any increase in serum HBV DNA by $>1 \log_{10}$ copies/ml from nadir or redetection of serum HBV DNA at levels 10-fold the lower limit of detection of the HBV DNA assay after having an undetectable result. Table 4 shows the patient baseline demo-

graphics, HBV DNA levels, and viral resistance profiles. All patients were positive for HBeAg and had serum levels of HBV DNA $>6 \log_{10}$ copies/ml at baseline. The median period until the appearance of the mutation was 120 (68–224) weeks. Two of the 49 (4%) patients who had detectable HBV DNA at the end of the first year subsequently developed resistance to entecavir. Furthermore, 3 of 49 (6%) patients who had detectable HBV DNA at the end of the first year developed VBT. Fig. 4A and B show the cumulative percentages of VBT and entecavir-resistance cases analyzed by the Kaplan-Meier test.

Discussion

Long-term data are rare for nucleoside-naïve patients treated continuously for more than 4 years with entecavir at the recommended dose of 0.5 mg daily. The only available data [6,8] were generated from follow-up studies of two phase III registration trials [3,4] in which patients showing complete response and non-responders were taken off entecavir. In the rollover studies, entecavir was administered to these patients at 1-mg dose at varying periods after cessation of the initial treatment. This double dose of entecavir was also given to patients showing a partial virological response after 48–96 weeks of entecavir at 0.5 mg daily. The present study has several unique features addressing specific and unanswered questions about entecavir treatment. It provided long-term results with respect to antiviral potency, viral resistance, and clinical safety for treatment-naïve patients who were treated continuously with entecavir at 0.5 mg daily for 4 years. Specifically, we found excellent viral suppression with 96% of patients achieving undetectable HBV DNA levels, only 1.1% (5/475) chance of viral breakthrough, and no clinically serious side effects after 4 years of treatment.

Genotype B was a significant factor associated with undetectable HBV DNA after the first year, although there were no significant differences after subsequent years. Previous studies showed conflicting results on the effect of HBV genotype on the response to lamivudine, with genotypes A, B, and C not affecting the antiviral response to lamivudine [14–16]. However, we have previously found that 47%, 84%, and 76% of patients had undetectable HBV DNA after the third year among patients of genotype

Table 4. Characteristics of patients with virologic breakthrough.

Patient No.	1	2	3	4	5
Age (yr)/gender	40/M	28/M	39/M	51/F	64/M
At start of entecavir therapy					
HBeAg status	+	+	+	+	+
HBV DNA (\log_{10} copies/ml)	>7.6	>7.6	7.2	7.2	6.2
HBV genotype	H	A	C	C	C
Viral load at maximum suppression (\log_{10} copies/ml)	<2.6	<2.6	<2.6	3.1	<2.6
Time of detection of mutation (wk)	83	224	120	68	145
HBV DNA (\log_{10} copies/ml), maximum	6.8	7.2	7.1	7.6	7.8
Mutational pattern	L180M+/S202G+/M204V	L180M+/T184I+/S202G+/M204V	L180M+/M204V, L180M+/M204I	A181T	A181S+/T184A+/M204I

A, B, and C, respectively [17,18]. The difference among these groups was probably due to the younger age of patients of genotype A and that they were often positive for HBeAg compared to those of genotype B or C. However, the genotype was not a significant predictor of HBV DNA loss after >2 years of entecavir therapy in the present study. There was also no difference in HBeAg seronegativity with entecavir among patients infected with genotype A, B, or C virus. These results were consistent with studies on lamivudine therapy [14,18].

In this study, HBeAg positivity was a significant factor associated with detectable HBV DNA at years 1 through 3, and these results were consistent with those reported by Zoutendijk *et al.* [10]. In addition, lower HBV DNA and HBeAg negativity at baseline were associated with enhanced response to lamivudine therapy [18–20]. We have also previously reported that lamivudine induced a better response in HBeAg-negative patients with higher levels of serum ALT [17]. The most important factor of long-term entecavir therapy therefore was low HBV DNA level.

Low HBV DNA level at baseline correlated significantly with HBeAg seroclearance, but not with seroconversion. One of the reasons was that patients who showed HBeAg seroclearance but no seroconversion had lower HBV DNA (median; $6.7 \log_{10}$ copies/ml) at baseline compared to patients with seroconversion (median; $7.5 \log_{10}$ copies/ml, $p = 0.005$).

Univariate analysis showed that age (>40 years), serum albumin level (<3.5 g/dl), and platelet count (< $20 \times 10^4/\text{mm}^3$) correlated with HBeAg seroconversion rate. We also investigated the correlation between serum albumin and other factors. Serum albumin level correlated significantly with age ($r = -0.378$, $n = 216$, $p < 0.001$), platelet count ($r = 0.262$, $n = 215$, $p < 0.001$), AFP ($r = -0.372$, $n = 161$, $p < 0.001$), cirrhosis ($P < 0.001$) and male sex ($p = 0.004$). Multivariate analysis identified low serum albumin level (<3.5) as the only significant determinant of HBeAg seroconversion. In this regard, Chien *et al.* [21] reported that pre-treatment ALT was the only significant determinant of HBeAg seroconversion during lamivudine therapy. The reasons for the different findings are probably related to the study design. In our study, the age of patients at baseline was higher (47 vs. 32 years) and the duration of treatment was longer (2.4 [median] vs. 1 year) than in the study of Chien *et al.* [21]. Furthermore, differences in the pharmacodynamics of lamivudine and entecavir could also contribute to the observed differences between the two studies.

On the other hand, resistant mutants and breakthrough hepatitis seemed to be less frequent during long-term therapy with entecavir than with lamivudine [16–19], indicating that entecavir is better than lamivudine for long-term treatment of CHB and cirrhosis patients. Tenney *et al.* [6] reported that 9 out of 663 (1.4%) patients had baseline lamivudine-resistant mutations, and other studies also found only small numbers of preexisting lamivudine-resistant mutations in treatment-naïve patients [22–24]. It is known that the HBV rtM204V (usually with concomitant rt180M) mutation often acquires one of the entecavir signature mutations at rt184, rt202, or rt250 over long-term treatments and patients develop clinical HBV DNA breakthroughs. Although *in vitro* studies showed that rt204I mutations with or without rt180M conferred 3- to 21-fold decrease in entecavir susceptibility [25], in clinical practice, patients with rt204I mutations, even with the entecavir signature mutations, have lower levels of phenotypic resistance to entecavir and can often achieve undetectable HBV DNA levels [6,9,26]. Interestingly, there were three

patients in the present study with VBT who had no HBV DNA mutations at rt184, rt202, or rt250 with rt180M and rt204V (entecavir-resistance). The rtM204V/I mutation, lamivudine's signature mutation, is necessary but not sufficient for entecavir-resistance, causing an 8- to 10-fold decrease in susceptibility to entecavir compared with wild-type HBV. Other mutations at positions rt184, rtS202, and rtM250 confer additional decreases in entecavir susceptibility [25,27,28]. In the present study, two patients (Patients #3 and 5) with mutations at position rtM204V/I, without rt184, rtS202, or rtM250 mutations, showed emergence of VBT, as did one patient (Patient #4) with an rtA181T mutation, which was first reported in a LAM-treated patient [29]. Although the rtA181T mutation is related to resistance to adefovir dipivoxil, this mutation has not been linked to additional decreases in entecavir susceptibility. Future *in vitro* analyses using replication-competent HBV clones in patients with rtA181T mutations are therefore necessary.

In conclusion, long-term treatment of treatment-naïve CHB patients with 0.5 mg/day entecavir for 4 years suppressed HBV DNA to undetectable levels in more than 90% of patients, regardless of HBeAg status and genotype. Moreover, the drug was very safe and rarely induced resistance mutations. Further studies exploring the therapeutic efficacy over longer durations may be necessary to confirm these findings.

Conflict of interest

Hiroimitsu Kumada has received speaker's honoraria from Bristol-Myers Squibb. All other authors declare no conflict of interest.

Financial support

This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare, Japan.

References

- [1] Lavanchy D. Hepatitis B. Virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004;11:97–107.
- [2] For the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver, Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. *Hepatol Int* 2008;2:263–283.
- [3] For BEHoLD A1463022 Study Group, Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006;354:1001–1010.
- [4] For BEHoLD A1463027 Study Group, Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006;354:1011–1020.
- [5] Colonna RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside-naïve patients with hepatitis B. *Hepatology* 2006;44:1656–1665.
- [6] Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology* 2009;49:1503–1514.
- [7] Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. *J Hepatol* 2010;52:791–799.
- [8] Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. *Hepatology* 2010;51:422–430.
- [9] Yuen M-F, Seto W-K, Fung J, Wong DK-H, Yuen JC-H, Lai C-L. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B

Research Article

- patients: Viral suppression, viral resistance, and clinical safety. *Am J Gastroenterol* 2011;106:1264–1271.
- [10] For the VIRGIL Surveillance Study Group, Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. *Hepatology* 2011;54:443–451.
- [11] Furusyo N, Nakashima H, Kashiwagi K, Kubo N, Hayashida K, Usuda S, et al. Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. *Am J Trop Med Hyg* 2002;67:151–157.
- [12] Matsuyama K, Hayashi K, Miura T. The quantitative assay for HBV DNA and the detection of HBV DNA point mutation by polymerase chain reaction—'AMPLICOR HBV MONITOR test' and 'HBV pre core/core promoter mutation detection kit. *Kan Tan Sui* 2000;41:59–71.
- [13] Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naïve patient with hepatitis B of genotype H. *J Clin Virol* 2007;39:149–152.
- [14] Chan HL, Wong ML, Hui AY, Chim AM, Tse AM, Hung LC, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. *World J Gastroenterol* 2003;9:2695–2697.
- [15] Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. *Antivir Ther* 2003;8:531–534.
- [16] Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. *J Viral Hepat* 2005;12:398–404.
- [17] Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. *Intervirology* 2003;46:182–189.
- [18] Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Arase Y, Ikeda K, et al. Response to Long-term lamivudine treatment in patients infected with hepatitis b virus genotypes A, B, and C. *J Med Virol* 2006;78:1276–1283.
- [19] Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. *Asia Hepatitis Lamivudine Study Group. N Engl J Med* 1998;339:61–68.
- [20] Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. *J Viral Hepat* 2002;9:393–399.
- [21] Chien R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis b e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. *Hepatology* 1999;30:770–774.
- [22] Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. *J Hepatol* 2001;34:584–586.
- [23] Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. *J Hepatol* 2002;37:259–265.
- [24] Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, et al. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. *J Med Virol* 2004;74:361–366.
- [25] Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. *J Hepatol* 2008;48:895–902.
- [26] Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. *Hepatology* 2008;47:1473–1482.
- [27] Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. *Antimicrob Agents Chemother* 2004;48:3498–3507.
- [28] Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. *Infect Drug Resist* 2011;4:55–64.
- [29] Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. *Hepatology* 2000; 31:1318–1326.

Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection

Nami Mori · Fumitaka Suzuki · Yusuke Kawamura · Hitomi Sezaki · Tetsuya Hosaka · Norio Akuta · Masahiro Kobayashi · Satoshi Saito · Yoshiyuki Suzuki · Yasuji Arase · Kenji Ikeda · Mariko Kobayashi · Hiromitsu Kumada

Received: 24 August 2011 / Accepted: 7 February 2012 / Published online: 29 February 2012
© Springer 2012

Abstract

Background Severe acute exacerbation of chronic hepatitis B can sometimes occur and lead to hepatic failure and death. The objective of this study was to elucidate the predictors of progression to hepatic decompensation during severe acute exacerbation.

Methods We prospectively analyzed 37 consecutive patients with acute exacerbation of chronic hepatitis B (accompanied by jaundice and coagulopathy) for clinical outcome and factors that influenced the development of severe acute exacerbation, including viral kinetics.

Results Fourteen (37.8%) patients progressed to severe acute exacerbation (accompanied by encephalopathy). Multivariate analysis identified serum bilirubin (>5 mg/dl, $P = 0.002$) as a significant determinant of progression to hepatic failure and prothrombin activity ($<45\%$, $P = 0.028$) and as a determinant of liver-related death. The hepatitis B virus (HBV) DNA level before therapy was measured in 25 patients. HBV DNA levels increased or did not change from before commencement of treatment in all 11 patients who progressed to severe acute exacerbation. On the other hand, HBV DNA levels did not change or increased in 8 of 14 patients (57%) with acute exacerbation ($P = 0.02$).

Conclusions Serum bilirubin and prothrombin activities were significant predictors of clinical outcome in patients with severe acute exacerbation of chronic hepatitis B. Viral kinetics until commencement of therapy can predict the severity of acute exacerbation of chronic hepatitis B.

Keywords Hepatitis B · Acute exacerbation · HBV DNA · Genotype · Encephalopathy

Abbreviations

AE	Acute exacerbation
ALT	Alanine aminotransferase
BCP	Basal core promoter
CS	Corticosteroid
HBV	Hepatitis B virus
IFN	Interferon
LMV	Lamivudine
NA	Nucleos(t)ide analogue
PC	Pre-core
PT	Prothrombin activity
SAE	Severe acute exacerbation

Introduction

More than 3 billion people worldwide and approximately 1.5 million people in Japan are chronically infected with hepatitis B virus (HBV), and chronic HBV infection is one of the most common causes of chronic hepatic failure and hepatocellular carcinoma (HCC) [1, 2]. Other complications of HBV infection include fulminant hepatitis and acute liver failure [3, 4]. Acute exacerbation (AE) in HBV carriers occurs either through a natural course [5, 6] or following intensive chemotherapy or immunosuppressive

N. Mori · F. Suzuki (✉) · Y. Kawamura · H. Sezaki · T. Hosaka · N. Akuta · M. Kobayashi · S. Saito · Y. Suzuki · Y. Arase · K. Ikeda · H. Kumada
Department of Hepatology, Toranomon Hospital,
2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
e-mail: fumitakas@toranomon.gr.jp

M. Kobayashi
Research Institute for Hepatology,
Toranomon Hospital, Tokyo, Japan